There are no bad anticancer agents, only bad clinical trial designs- twenty-first Richard and Hinda Rosenthal foundation award lecture

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1079-1086

  Von Hoff, Daniel D ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUDARABINE PHOSPHATE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOGUAZONE; PACLITAXEL; VINCRISTINE;

ANAPHYLACTIC SHOCK; ANTINEOPLASTIC ACTIVITY; BLINDNESS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG DESIGN; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DEOXYCYTIDINE; EFLORNITHINE; HUMANS; MITOGUAZONE; NEOPLASMS; RESEARCH DESIGN;

EID: 0031896592     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Von Hoff, D. D. MGBG: teaching an old drug new tricks. Ann. Oncol., 5: 487-493, 1994.
2. Thiele, J., and Dralle, F. Zur Kenntnis des amino gunidins. I. Condensations-produkte de amidoguanidins mit aldehyden and ketonen der fettreihe. Justus Liebigs Ann. Chem., 302: 275-299, 1898.
3. Corti, A., Dave, C., Williamson-Ashman, H. G., Mihich, E., and Schenone, A. Specific inhibition of the enzymatic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem. J., 139: 351-357, 1974.
4. Pleshkewych, A., Kramer, D. L., Kelly, E., and Porter, C. W. Independence of drug action on mitochondria and polyamines in L1210 leukemia cells treated with methylglyoxal bis(guanylhydrazone). Cancer Res., 40: 4533-4540, 1980.
5. Pine, M. J., and DiPaolo, J. The antimitochondrial actions of 2-chloro-4′,4″-bis(2-imidazolin 2-yl)-terephthalanilide and methylglyoxal bis(guanylhydrazone). Cancer Res., 26: 18-25, 1966.
6. Freireich, E., Frei, E., III, and Karon, M. Methylglyoxal bis(guanylhydrazone): a new agent active against acute myelocytic leukemia. Cancer Chemother. Rep., 16: 183-186, 1962.
7. Regelson, W., and Holland, J. F. Clinical experience with methylglyoxal bis(guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas. Cancer Chemother. Rep., 27: 15-26, 1963.
8. Levin, R. H., Henderson, E., Karon, M., and Freireich, E. J. Treatment of acute leukemia with methylglyoxal bis(guanylhydrazone) (methyl-GAG). Clin. Pharmacol. Ther., 6: 31-42, 1964.
9. Marsh, K. C., Liesmann, J., Patton, T. F., Fabian, C. J., and Sternson, L. A. Plasma levels and urinary excretion of methyl-GAG following i.v. infusion in man. Cancer Treat. Rep., 65: 253-257, 1981.
10. Hart, R. D., Roboz, J., Wu, K., Bruckner, T., Ohnuma, T., and Holland, J. F. Clinical and pharmacologic studies with weekly and biweekly methylglyoxal bis-guanylhydrazone (methyl-G). Proc. Am. Assoc. Cancer Res., 21: 181, 1980.
11. Rizzo, J., Levine, A. M., Weiss, G. R., Pearce, T., Kraynak, M., Mueck, R., Smith, S., Von Hoff, D. D., and Kuhn, J. G. Pharmacokinetics profile of mitoguazone (MGBG) in patients with AIDS-related non-Hodgkin's lymphoma. Invest. New Drugs, 14: 227-234, 1996.
12. Knight, W. A., III, Fabian, C., Costanzi, J. J., Jones, S. E., and Coltman, C. A., Jr. Methylglyoxal bis-guanylhydrazone (methyl GAG, MGBG) in lymphoma and Hodgkin's disease. Invest. New Drugs, 1: 225-237, 1983.
13. Warrell, R. P., Lee, B. J., Kempin, S. J., Lacher, M. J., Straus, D. J., and Young, C. W. Effectiveness of methyl-GAG (methylglyoxal-bis-[guanylhydrazone]) in patients with advanced malignant lymphoma. Blood, 57: 1011-1014, 1981.
14. Warrell, R. P., and Burchenal, J. H. Methylglyoxal- bis(guanylhydrazone) (methyl GAG): current studies and future prospects. J. Clin. Oncol., 1: 52-65, 1983.
15. Luedke, D. W., Maddox, W., Birch, R., Velez-Garcia, E., and Schleuter, J. Mitoguazone in advanced squamous cell carcinoma of head and neck origin: a Phase II trial of the Southeastern Cancer Study Group. Cancer Treat. Rep., 70: 529-530, 1986.
16. Scher, H. I., Yagoda, A., Ahmed, T., and Watson, R. C. Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate. J. Clin. Oncol., 3: 224-228, 1985.
17. Karp, J. E., and Broders, S. Acquired immunodeficiency syndrome and non-Hodgkin's lymphoma. Cancer Res., 51: 4743-4756, 1991.
18. Levine, A. Acquired immunodeficiency syndrome related lymphoma. Blood, 80: 8-20, 1992.
19. Kaplan, L. D., Straus, D. J., Testa, M. A., Van Roenn, J., Dezube, B. J., Cooley, T. P., Herndier, B., Northfelt, D. W., Huang, J., Tulpule, A., and Levine, A. M. Low-dose compared with standard-dose mBACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N. Engl. J. Med., 336: 1641-1648, 1997.
20. Russell, D. H., Levy, C. C., Schimpft, S. C., and Hawk, I. A. Urinary polyamine in cancer patients. Cancer Res., 31: 1555-1558, 1971.
21. Russell, D. H. Increased polyamine concentrations in the urine of human cancer patients. Nature (Lond.), 233: 144-145, 1971.
22. Rosenblum, M. G., Stewart, D. J., Yap, B. S., Leavens, M., Benjamin, R. S., and Loo, T. L. Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans. Cancer Res., 41: 459-462, 1981.
23. Levine, A. M., Tulpule, A., Tessman, D., Kaplan, L., Giles, F., Luskey, B. D., Scadden, D. T., Northfelt, D., Silverberg, I., Wernz, J., Espina, B., and Von Hoff, D. D. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicancer Phase II trial. J. Clin. Oncol., 15: 1094-1103, 1997.
24. Levine, A. M., Giles, F., Kaplan, L, Sparano, J., Scadden, D., Luskey, B., Northfelt, D., Thommas, J., Anderson, L. J. J., Espina, B., Tessman, D., and Von Hoff, D. Two sequential prospective, multi-institutional Phase II clinical trials of mitoguazone (MGBG) in refractory or relapsed AIDS-related lymphoma. Blood, 86 (Suppl 1): 381a, 1995.
25. Staquet, M. J., Byar, D. P., Green, S. P., and Rozenwey, M. Clinical productivity of transplantable tumor system in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat. Rep., 67: 753-765, 1983.
26. Twentyman, P. Drug screening in xenografts: the European multi-center project. Ann. Oncol., 5: 394-396, 1994.
27. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
28. Heinemann, V., Hertel, L., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluoro-deoxycytidine and 1-β-D-arabinofuranosyl cytosine. Cancer Res., 48: 4024-4031, 1988.
29. Ghandi, V., and Plunkett, W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res., 50: 3675-3680, 1990.
30. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
31. Hanauske, A., Degen, D., Marshall, M. H., Hilsenbeck, S. G., Grindey, G. B., and Von Hoff, D. D. Activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human tumor colony forming units. Anticancer Drugs, 3: 143-146, 1992.
32. O'Rourke, T. J,. Brown, T. D., Havlin, K., Kuhn, J. G., Craig, J. B., Burris, H. A., Satterlee, P. G., Tarassoff, F., and Von Hoff, D. D. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur. J. Cancer, 30A: 417-418, 1994.
33. Brown, T., O'Rourke, T., Burris, H., Kuhn, J., Tarassoff, P., Cagnola, J., Rodriguez, G., and Von Hoff, D. A Phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 10: 115, 1991.
34. Casper, E. S., Green, M. R., Brown, T. D., Kelsen, D. P., Kresek, T., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with pancreatic cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 10: 143, 1991.
35. Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-34, 1994.
36. Warshaw, A. L., and Fernandez-del Castillo, C. Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465, 1992.
37. Kelsen, D. P., Portenoy, R. K., Thaler, H. T., Niedzwiecki, D., Passik, S. D., Tao, Y., Banks, W., Brennan, M. F., and Foley, F. M. Pain and depression in patients with newly diagnosed pancreas cancer. J. Clin. Oncol., 13: 748-755, 1995.
38. Fishman, B., Pasternak, S., and Wallenstein, S. L. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer (Phila.), 60: 1151-1158, 1987.
39. Andersen, J. S., Burris, H. A., Casper, E., Clayman, M., Green, M., Nelson, R. L., Portenoy, R., Rothenberg, M., Tarassoff, P. G., and Von Hoff, D. D. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 461, 1994.
40. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest. New Drugs, 10: 239-253, 1992.
41. Moore, M., Andersen, J., Burris, H., Tarassoff, P., Green, M., Casper, E., Portenoy, R., Modiano, M., Cripps, C., Nelson, R., Storniolo, A., and Von Hoff, D. D. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 199, 1995.
42. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
43. Rothenberg, M. L., Moore, M. J., Cripps, M. C., Andersen, J. S., Portenoy, R. K., Burris, H. A., III, Green, M. R., Tarassoff, P. G., Brown, T. D., Casper, E. S., Storniolo, A-M., and Von Hoff, D. D. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 7: 347-353, 1996.
44. Carmichael, J., Fink, U., Russell, R. C., Spittle, M. F., Harris, A., Spiessel, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1995.
45. Bey, P., Danzin, C., Von Dorsselaer, V., Mamont, P., Jung, M., and Tardif, C. Analogues of ornithine as inhibitors of ornithine decarboxylase: new deductions concerning the topography of the enzyme's active site. J. Med. Chem., 21: 50-55, 1978.
46. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res., 48: 759-784, 1988.
47. Mitchell, M. F., Tortolero-Luna, G., Lee, J. J., Hittelman, W. N., Lotan, R., Wharton, J. T., Hong, W. K., and Nishioka, K. Phase I dose-escalation trial of α-difluoromethylornithine in patients with cervical intraepithelial neoplasia grade 3. Clin. Cancer Res., 4: 303-310, 1998.
48. Porter, C., Herrera-Ornelas, L., Pera, P., Retrelli, N. F., and Mittelman, A. Polyamine biosynthetic activity in normal and neoplastic human colorectal tissue. Cancer (Phila.), 60: 1275-1281, 1987.
49. Garewal, H. S., Sampliner, R., Gerner, E., Steinbronn, K., Alberts, D., and Kendall, D. Ornithine decarboxylase activity in Barrett's esophagus: a potential marker for dysplasia. Gastroenterology, 94: 819-821, 1988.
50. Manni, A., Mauger, D., Gimotty, P., and Badges, B. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin. Cancer Res., 2: 1401-1406, 1996.
51. Auvinen, M., Paasinen, A., Anderson, L. C., and Holtta, E. Ornithine decarboxylase activity is critical for cell transformation. Nature (Lond.), 360: 355-358, 1992.
52. Thompson, H. J., Meeker, L. D., Herbst, E. J., Ronan, A. M., and Minocha, R. Effect of concentration of DL-α-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res., 45: 1170-1173, 1985.
53. Reddy, B. S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with DL-α-difluoromethylornithine on ornithine decarboxylase inhibitor. Cancer Res., 50: 2562-2568, 1990.
54. Homma, Y., Kakizoe, T., Samma, S., and Oyasu, R. Inhibition of N-butyl-N (hydroxybutyl) nitrosamine-induced rat urinary bladder carcinogenesis by α-difluoromethylornithine. Cancer Res., 47: 6176-6179, 1987.
55. Weeks, C. E., Herrimann, A. L., Nelson, F. R., and Sloga, T. J. Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in the mouse skin. Proc. Natl. Acad. Sci. USA, 74: 6028-6032, 1982.
56. Abeloff, M. D., Slavik, M., Luk, G. D., Griffen, C. A., Hermann, J., Blanc, O., Sjoerdsman, A., and Baylin, S. B. Phase I and pharmacokinetic studies of α-difluoromethylomithine-an inhibitor of polyamine biosynthesis. J. Clin. Oncol., 2: 124-130, 1984.
57. Griffin, D. A., Slavik, M., Chien, S. C., Hermann, J., Thompson, G., Blanc, O., Luk, G. D., Baylin, S. B., and Abeloff, M. D. Phase I trial and pharmacokinetic study of intravenous and oral α-difluoromethylornithine. Invest. New Drugs, 5: 177-186, 1987.
58. Love, R. R., Carbone, P. P., Vermia, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplun, M., and Wilding, G. Randomized Phase I Chemoprevention dose-seeking study of α-difluoromethylomithine. J. Natl. Cancer Inst., 85: 732-737, 1993.
59. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Doody, L. A. Surrogate endpoint biomarkers for Phase II cancer Chemoprevention trials. J. Cell. Biochem., 19: 1-9, 1994.
60. Meyskens, F. L., Jr., Emerson, D. S., Pelot, D., Meshkinpour, H., Shassetz, L. R., Einspahr, J., Alberts, D. S., and Gerner, E. W. Dose de-escalation Chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J. Natl. Cancer Inst., 86: 1122-1130, 1994.
61. Alberts, D. S., Dorr, R. T., Aikin, M., Quinn, J., Goldman, R., Nelson, M., Xu, M. J., Peng, Y. M., Bozzo, P., and Gensler, H. Positive randomized, double-blinded, placebo-controlled study of topical difluoromethylornithine (DFMO) in the Chemoprevention of skin cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 172, 1996.
62. Schipper, H., Goh, C. R., and Wang, T. L. Shifting the cancer paradigm: must we kill to cure? J. Clin. Oncol., 13: 801-807, 1994.